A recent study published in [object Object] explored the prognostic significance of measurable residual disease (MRD) assessment prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The study, conducted over 20 years from 2000 to 2020, included 192 patients who underwent allo-HSCT in complete remission (CR) or CR with incomplete hematologic recovery.
Key Findings:
- MRD-negative patients had markedly better overall survival (OS) and disease-free survival (DFS) compared with their MRD-positive counterparts, with a median OS of 130.6 months for MRD-negative patients versus just 16.0 months for MRD-positive patients ( P < .001).
- The median DFS was 109.6 months for MRD-negative patients, compared with only 7.1 months for those with MRD positivity ( P < .001).
- Cumulative incidence of relapse (CIR) at 12 months also varied significantly by MRD status, with MRD-negative patients experiencing a relapse rate of 7.3%, while MRD-positive patients had a much higher rate of 33.7%.
Subgroup Analysis:
- MRD-positive status was associated with significantly lower DFS in patients with AML, patients under 60 years old, and those within the European LeukemiaNet 2017 adverse-risk category.
- The impact was not observed in patients with MDS and those aged 60 years or older.
Methodological Insights:
- Combining multiparametric flow cytometry (MFC) and molecular PCR techniques to assess MRD is crucial due to noted discrepancies.
- WT1-MRD assessment was effective in predicting DFS in both MRD-positive and MRD-negative patients, highlighting its potential as a reliable tool for guiding clinical decisions.
Conclusion:
The study confirms that MRD status prior to allo-HSCT is a strong prognostic factor for OS, DFS, and CIR, emphasizing the importance of integrating MRD assessment into clinical practice and treatment decision-making to optimize treatment outcomes, particularly for patients with AML.
